Downsizing of Unresectable Cholangiocarcinoma by Combined Intravenous and Intra-arterial Chemotherapy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Cholangiocellular Carcinoma
Interventions
DRUG

Selective intra-arterial floxuridine and systemic gemcitabine and cisplatin

"Intra-arterial floxuridine:0.2 mg/KG/day for 14 days, repeated day 29. Overall 3 applications.~Systemic cisplatin: 25 mg/m2 at days 1 and 8, repeated day 22. Overall 8 applications.~Systemic gemcitabine: Three different dose levels will be tested; 600 mg/m2, 800 mg/m2, or 1000 mg/m2, at days 1 and 8, repeated day 22. Overall 8 applications."

Trial Locations (1)

8091

University Hospital Zurich, Department of Oncology, Zurich

All Listed Sponsors
lead

University of Zurich

OTHER

NCT01692704 - Downsizing of Unresectable Cholangiocarcinoma by Combined Intravenous and Intra-arterial Chemotherapy | Biotech Hunter | Biotech Hunter